Literature DB >> 19684903

Recognition of subtype non-small cell lung cancer by DNA aptamers selected from living cells.

Zilong Zhao1, Li Xu, Xiaoli Shi, Weihong Tan, Xiaohong Fang, Dihua Shangguan.   

Abstract

In this work, we have developed new aptamer probes for non-small cell lung cancer (NSCLC) by directing the aptamer selection process against the living cells of adenocarcinoma, the most common subtype of NSCLC. A panel of single-stranded DNA (ssDNA) aptamers were generated and evaluated for adenocarcinoma cell recognition. The aptamers bound to the adenocarcinoma cells with dissociation constants in the nanomolar range and the binding of the selected aptamers to the adenocarcinoma cells were significantly stronger than the other cancerous lung cells as well as other types of cancer cells. Moreover, the application of the aptamers to the clinical tissue section samples showed the differentiation of adenocarcinoma from normal lung tissue and other subtypes of lung cancer. The aptamers are expected to be new molecular probes for the investigation of the molecular bases of different NSCLC subtypes and their biological heterogeneity, which is valuable for advancing NSCLC diagnosis and treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19684903     DOI: 10.1039/b904476k

Source DB:  PubMed          Journal:  Analyst        ISSN: 0003-2654            Impact factor:   4.616


  55 in total

Review 1.  Recent developments in protein and cell-targeted aptamer selection and applications.

Authors:  Jun Liu; Mingxu You; Ying Pu; Huixia Liu; Mao Ye; Weihong Tan
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 2.  Molecular aptamers for drug delivery.

Authors:  Weihong Tan; Hui Wang; Yan Chen; Xiaobing Zhang; Haizhen Zhu; Chaoyong Yang; Ronghua Yang; Chen Liu
Journal:  Trends Biotechnol       Date:  2011-08-06       Impact factor: 19.536

3.  Immunocytochemistry Based on a Cell-Type-Specific Aptamer for Rapid Immunostaining of Adenocarcinoma Cells in Clinical Serosal Fluids.

Authors:  Yunmei Zhang; Jieru Xu; Dairong Li; Tao Wan; Qianfang Hu
Journal:  Pathol Oncol Res       Date:  2018-11-26       Impact factor: 3.201

Review 4.  Aptamers as Therapeutics.

Authors:  Shahid M Nimjee; Rebekah R White; Richard C Becker; Bruce A Sullenger
Journal:  Annu Rev Pharmacol Toxicol       Date:  2017-01-06       Impact factor: 13.820

Review 5.  Clinical applications of nucleic acid aptamers in cancer.

Authors:  Xiaoyu Pei; Jun Zhang; Jie Liu
Journal:  Mol Clin Oncol       Date:  2014-02-10

6.  Catalytic self-assembly of a DNA dendritic complex for efficient gene silencing.

Authors:  Yifan Lv; Ruizi Peng; Yu Zhou; Xiaobing Zhang; Weihong Tan
Journal:  Chem Commun (Camb)       Date:  2016-01-25       Impact factor: 6.222

Review 7.  Aptamers selected by cell-SELEX for application in cancer studies.

Authors:  Yunfei Zhang; Yan Chen; Da Han; Ismail Ocsoy; Weihong Tan
Journal:  Bioanalysis       Date:  2010-05       Impact factor: 2.681

Review 8.  Aptamer-based targeted therapy.

Authors:  Guizhi Zhu; Xiaoyuan Chen
Journal:  Adv Drug Deliv Rev       Date:  2018-08-17       Impact factor: 15.470

9.  Study of the molecular recognition of aptamers selected through ovarian cancer cell-SELEX.

Authors:  Dimitri Van Simaeys; Dalia López-Colón; Kwame Sefah; Rebecca Sutphen; Elizabeth Jimenez; Weihong Tan
Journal:  PLoS One       Date:  2010-11-01       Impact factor: 3.240

10.  Identification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40.

Authors:  Elizabeth D Pratico; Bruce A Sullenger; Smita K Nair
Journal:  Nucleic Acid Ther       Date:  2012-10-31       Impact factor: 5.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.